文献速递淋巴瘤造血干细胞移植与细胞治疗

维布妥昔单抗治疗不适合干细胞移植或多药化疗的复发/难治性霍奇金淋巴瘤患者的前瞻性研究

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
PubMed 文献 · Br J Haematol · 2018-08-30

这项IV期研究纳入60例不适合干细胞移植或多药化疗的CD30阳性复发/难治性霍奇金淋巴瘤患者,接受维布妥昔单抗1.8 mg/kg每3周一次静脉给药。独立评审的总缓解率为50%(完全缓解12%),47%的患者后续接受干细胞移植;中位缓解持续时间4.6个月,中位完全缓解持续时间6.1个月;中位随访6.9个月时中位无进展生存期4.8个月(95%CI 3.0-5.3),中位随访16.6个月时中位总生存期未达到,12个月估计总生存率86%。

要点

  • 维布妥昔单抗1.8 mg/kg每3周一次治疗不适合移植或多药化疗的复发/难治性霍奇金淋巴瘤,独立评审总缓解率50%,完全缓解率12%。
  • 47%的患者后续接受干细胞移植;中位缓解持续时间4.6个月,中位完全缓解持续时间6.1个月。
  • 中位无进展生存期4.8个月(95%CI 3.0-5.3),12个月估计总生存率86%;常见不良事件为周围神经病变(35%)、发热(18%)、腹泻和中性粒细胞减少(各10%)。

核心结论

  • 维布妥昔单抗显示出显著活性,安全性特征与已知毒性一致,可能作为干细胞移植的桥接治疗,使一线/挽救化疗/放疗后缓解不理想的高危患者能够接受潜在治愈性的干细胞移植。

研究设计与样本

  • IV期研究(NCT01990534),纳入60例年龄≥18岁、CD30阳性复发/难治性霍奇金淋巴瘤、既往接受过≥1种全身化疗方案、被判定不适合干细胞移植或多药化疗的患者。
  • 维布妥昔单抗1.8 mg/kg静脉给药,每3周一次。
  • 主要终点为独立评审机构评估的总缓解率;次要终点包括缓解持续时间、独立评审机构评估的无进展生存期、总生存期、后续接受干细胞移植的比例及安全性。

主要发现

  • 总缓解率为50%,其中完全缓解12%;47%的患者后续接受干细胞移植。
  • 中位缓解持续时间为4.6个月,中位完全缓解持续时间为6.1个月。
  • 中位随访6.9个月时,中位无进展生存期为4.8个月(95%置信区间3.0-5.3)。
  • 中位随访16.6个月时,中位总生存期未达到;12个月估计总生存率为86%。
  • 最常见不良事件(≥10%)包括周围神经病变(35%)、发热(18%)、腹泻和中性粒细胞减少(各10%)。

临床怎么用

  • 作者认为,维布妥昔单抗可能作为干细胞移植的桥接治疗,使一线/挽救化疗/放疗后缓解不理想的高危患者能够接受潜在治愈性的干细胞移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks) in 60 patients (aged ≥18 years) with CD30-positive relapsed/refractory HL, a history of ≥1 prior systemic chemotherapy regimen, who were considered unsuitable for SCT/multi-agent chemotherapy. Primary endpoint was overall response rate (ORR) per independent review facility (IRF). Secondary endpoints included duration of response (DOR), progression-free survival (PFS) per IRF, overall survival (OS), proportion proceeding to SCT and safety. The ORR was 50%, with 12% CR; 47% proceeded to SCT. Median DOR was 4·6 months and median duration of CR was 6·1 months. After a median follow-up of 6·9 and 16·6 months, median PFS and OS were 4·8 months (95% confidence interval, 3·0-5·3) and not reached, respectively; estimated OS rate was 86% at 12 months. Most common adverse events (≥10%) were peripheral neuropathy (35%), pyrexia (18%), diarrhoea and neutropenia (each 10%). Brentuximab vedotin showed notable activity with a safety profile consistent with known toxicities, and may act as a bridge to SCT, enabling high-risk patients who achieve suboptimal response to frontline/salvage chemotherapy/radiotherapy to receive potentially curative SCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Walewski J, Hellmann A, Siritanaratkul N, et al. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. Br J Haematol. 2018. PMID: 30168134. doi:10.1111/bjh.15539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。